[A case of Stewart-Treves syndrome--treatment with recombinant interleukin 2 and a review of Japanese literature].
A 76-year-old woman developed angiosarcoma 11 years after a radical mastectomy in the chronic lymphedema of the ipsilateral arm, referred to as Stewart-Treves syndrome. The patient was treated by intravenous and intralesional injection of recombinant interleukin 2 (rIL-2; TGP-3, Takeda Chemical Industries, LTD, Osaka). Intralesional injection was more effective than systemic administration. After a month, the lesion where the local injection was done showed little tumor cells with a dense infiltrate composed of lymphoid cells. It was observed that NK activity, LAK activity and IL-2 receptor positive T-cells in the peripheral blood increased during the administration of rIL-2. As the lesion was too large to be treated with rIL-2 alone, radiotherapy was performed. But the patient had no remarkably improvement and died 16 months later from the onset. Immunotherapy with rIL-2 can be useful for angiosarcoma and more effective regimen of rIL-2 is a important problem.
Nabeya
R
R
Department of Dermatology, Chiba University School of Medicine.
Kobayashi
M
M
Fujita
M
M
Yorifuji
K
K
Eguchi
N
N
Okamoto
S
S
D000368:Aged; D001943:Breast Neoplasms / Q000601:surgery; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D007376:Interleukin-2 / Q000627:therapeutic use*; D008204:Lymphangiosarcoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008209:Lymphedema / Q000150:complications; D015409:Mastectomy, Radical; D009378:Neoplasms, Multiple Primary; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013577:Syndrome
D007376:Interleukin-2; D011994:Recombinant Proteins